Trial
NCT04954742
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Heidelberg University
Collaborators
Merck Sharp & Dohme LLC
Condition
Primary Pulmonary Arterial Hypertension
Intervention
Riociguat
Why stopped
Strategic re-prioritization by the IMP supplier. Decision not safety-related
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-17